Literature DB >> 1739635

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.

N H Mulder1, E G de Vries, D T Sleijfer, H Schraffordt Koops, P H Willemse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1739635      PMCID： PMC1977744          DOI： 10.1038/bjc.1992.61

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  4 in total

1.  Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.

Authors:  E T Creagan; D L Ahmann; S Frytak; H J Long; M N Chang; L M Itri
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

2.  Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites.

Authors:  L Elias; H A Crissman
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

3.  Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.

Authors:  N H Mulder; D T Sleijfer; E G de Vries; H Schraffordt Koops; M J Samson; P H Willemse
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.

Authors:  N H Mulder; P H Willemse; H Schraffordt Koops; E G de Vries; D T Sleijfer
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640
  4 in total
  2 in total

1.  Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.

Authors:  C I Falkson
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

2.  Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.

Authors:  N H Mulder; W T van der Graaf; P H Willemse; H S Koops; E G de Vries; D T Sleijfer
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.